Literature DB >> 4174401

Assessment of British gammaglobulin in preventing infectious hepatitis. A report to the director of the Public Health Laboratory Service.

.   

Abstract

A series of 87 controlled trials of the effectiveness of British gammaglobulin in preventing infectious hepatitis in schools and other institutions showed that gammaglobulin is very effective in these circumstances. No protection was given for the first two weeks after injection, probably because it was given during the incubation period of the hepatitis.The risks of developing hepatitis in contacts was found to vary greatly. In day schools there was usually little tendency for the disease to spread among the population, but the pupils in closest contact were at greater risk. In mental hospitals and children's homes, on the other hand, the tendency for the disease to spread was more pronounced.

Entities:  

Mesh:

Substances:

Year:  1968        PMID: 4174401      PMCID: PMC1986409     

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  2 in total

1.  Large scale production of human plasma fractions. Eight years experience with the alcohol fractionation procedure of Nitschmann, Kistler and Lergier.

Authors:  P KISTLER; H NITSCHMANN
Journal:  Vox Sang       Date:  1962 Jul-Aug       Impact factor: 2.144

2.  Infectious hepatitis; length of protection by immune serum globulin (gamma globulin) during epidemics.

Authors:  J STOKES; J A FARQUHAR; M E DRAKE; R B CAPPS; C S WARD; A W KITTS
Journal:  J Am Med Assoc       Date:  1951-10-20
  2 in total
  2 in total

1.  Viral hepatitis in United States soldiers stationed in Korea, 1967-1970: prophylactic efficacy of gamma globulin.

Authors:  H F Smetana; F G Smetana
Journal:  Bull N Y Acad Med       Date:  1976-06

Review 2.  Passive immunization for the public health control of communicable diseases: current status in four high-income countries and where to next.

Authors:  Megan K Young; Allan W Cripps
Journal:  Hum Vaccin Immunother       Date:  2013-06-19       Impact factor: 3.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.